Impairment Clinical Trials in Orlando, Florida
19 recruitingOrlando, Florida
Showing 1–19 of 19 trials
Recruiting
Phase 1
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
Renal Impairment
Incyte Corporation16 enrolled2 locationsNCT07559396
Recruiting
Phase 1
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
HealthyHepatic Impairment
Boehringer Ingelheim32 enrolled3 locationsNCT07023354
Recruiting
Phase 1
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Hepatic Impairment
Genentech, Inc.32 enrolled4 locationsNCT07144111
Recruiting
Phase 1
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
Severe Hepatic ImpairmentNormal Hepatic Function
Institut de Recherches Internationales Servier (I.R.I.S.)20 enrolled3 locationsNCT07250633
Recruiting
Phase 1
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
End Stage Renal DiseaseRenal ImpairmentChronic Kidney Failure
Merck Sharp & Dohme LLC24 enrolled3 locationsNCT07348237
Recruiting
Phase 1
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
HealthyHepatic Impairment
Pfizer26 enrolled3 locationsNCT07269301
Recruiting
Phase 1
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
HealthyRenal Impairment
Pfizer28 enrolled4 locationsNCT07315360
Recruiting
Phase 1
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
HealthyHepatic Impairment
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany32 enrolled3 locationsNCT06997276
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Memory DisordersMild Cognitive ImpairmentMemory Impairment+3 more
GAP Innovations, PBC1,200 enrolled26 locationsNCT06584357
Recruiting
Phase 1
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Healthy Volunteer StudyRenal ImpairmentHepatic Impairment
Atea Pharmaceuticals, Inc.28 enrolled2 locationsNCT06911320
Recruiting
Phase 1
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Kidney DiseaseRenal ImpairmentRenal Insufficiency, Chronic+3 more
Eli Lilly and Company28 enrolled2 locationsNCT07426380
Recruiting
Phase 1
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
Hepatic Impairment (HI)
Edgewise Therapeutics, Inc.32 enrolled2 locationsNCT07324616
Recruiting
Phase 1
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
HealthyHepatic Impairment
Merck Sharp & Dohme LLC58 enrolled3 locationsNCT07219550
Recruiting
Phase 1
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
Renal Impairment
AstraZeneca50 enrolled2 locationsNCT07154901
Recruiting
Phase 1
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Hepatic Impairment (HI)
Merck Sharp & Dohme LLC32 enrolled3 locationsNCT06442436
Recruiting
Phase 1
Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
Moderate Renal Impairment
Sparrow Pharmaceuticals16 enrolled1 locationNCT07227922
Recruiting
Phase 1
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
Renal Impairment
Shionogi40 enrolled4 locationsNCT07217886
Recruiting
Phase 1
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Moderate Hepatic ImpairmentHepatic Impairment
Exelixis20 enrolled2 locationsNCT06962332
Recruiting
Phase 1
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
Hepatic Impairment
Alumis Inc48 enrolled4 locationsNCT06952634